Zai Lab nabs speedy Chi­na reg­u­la­to­ry re­view for PARP drug Ze­ju­la

Chi­nese reg­u­la­to­ry of­fi­cials are sig­nal­ing that they’re ready to whisk Ze­ju­la through the reg­u­la­to­ry process.

Zai Lab $ZLAB said this morn­ing that the Cen­ter for Drug Eval­u­a­tion of Chi­na’s Na­tion­al Med­ical Prod­ucts Ad­min­is­tra­tion has of­fered a pri­or­i­ty re­view for this drug, the PARP ther­a­py ni­ra­parib in-li­censed from Tesaro. They’re look­ing for an OK in Chi­na to mar­ket the drug for ovar­i­an can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.